SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):145P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Hindorf, C.
Right arrow Articles by Parker, C.
PubMed
Right arrow Articles by Hindorf, C.
Right arrow Articles by Parker, C.

Oncology-Basic Science: Therapy, Metrics & Intervention

Imaging for Assesment of Response or Therapy Planning

A biodistribution and dosimetry study of therapeutic 223Ra-chloride (Alpharadin) in patients with osteoblastic skeletal metastases secondary to hormone refractory prostate cancer

Cecilia Hindorf1, Glenn Flux1, Val Lewington2, Anne-Kirsti Aksnes3, Peter Harris3 and Chris Parker4

1 Join Department of Physics, Royal Marsden Hospital & Institute of Cancer Research, Sutton, London, United Kingdom; 2 Department of Nuclear Medicine, Royal Marsden Hospital, Sutton, London, United Kingdom; 3 Algeta ASA, Oslo, Norway; 4 Department of Urology, Royal Marsden Hospital, Sutton, London, United Kingdom

576

Objectives: The purpose of the study was to investigate the pharmacokinetics and to determine the absorbed dose to relevant tissues following intravenous administration of 223Ra-chloride (Alpharadin) in patients with osteoblastic skeletal metastases.

Methods: Six patients with bone metastases from prostate cancer received two intravenous injections of 223Ra-chloride 100 kBq/kg body weight six weeks apart. Serial whole body measurements, quantitative planar scintillation camera imaging and blood sampling were performed following each injection. All urine and faeces were collected for 48 h post injection. The absorbed dose was calculated by the MIRD schema.

Results: The average percentage of injected activity excreted via faeces and urine at 48 hours post injection was 25% (range 0 – 52%) and 3% (range 1 – 9%), respectively. The median of the whole body absorbed dose was 0.18 Gy (range 0.14 – 0.52 Gy) per injection. The inter-patient pharmacokinetic variability for the whole body and blood was higher than the intra-patient variability. The self absorbed dose to the kidneys was less than 0.2 Gy per injection for all patients. Scintillation camera images demonstrated 223Ra accumulation in normal bone and skeletal metastases with gastrointestinal excretion.

Conclusions: The calculated absorbed doses to normal tissues following intravenous injections of 223Ra chloride injections of 100 kBq/kg are very low and unlikely to be a limiting factor in this patient population.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Hindorf, C.
Right arrow Articles by Parker, C.
PubMed
Right arrow Articles by Hindorf, C.
Right arrow Articles by Parker, C.